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Abstract
Background: To investigate the effects of intravenous lignocaine infusions (IV lignocaine) in
fibromyalgia.
Methods:  Prospective study of the adverse effects of IV lignocaine in 106 patients with
fibromyalgia; retrospective questionnaire study of the efficacy of IV lignocaine in 50 patients with
fibromyalgia.
Results: Prospective study: Two major (pulmonary oedema and supraventricular tachycardia) and
42 minor side-effects were reported. None had long-term sequelae. The commonest was
hypotension (17 cases). Retrospective study: Pain and a range of psychosocial measures (on single
11-point scales) improved significantly after treatment. There was no effect of the treatment on
work status. The average duration of pain relief after the 6-day course of treatment was 11.5 ± 6.5
weeks.
Conclusions: Intravenous lignocaine appears to be both safe and of benefit in improving pain and
quality of life for patients with fibromyalgia. This needs to be confirmed in prospective randomised
controlled trials.
Background
Fibromyalgia is a chronic syndrome with widespread con-
tinuous muscular pain at rest and tenderness to pressure
in at least 11 of 18 specified anatomical sites [1]. It is a
common condition with a prevalence in the adult popu-
lation of 2% [2] and causes considerable disability equiv-
alent to that seen in rheumatoid arthritis [3]. Chronicity is
the rule and disability and depression increase with dis-
ease duration [4].
Treatments fall into several classes: pharmacological, psy-
chological, physical and complementary therapies. Non-
steroidal anti-inflammatory drugs and steroids are un-
helpful [5,6]; tricyclic antidepressants are widely used but
their effect is modest [7,8]. Cognitive behavioural thera-
pies may be useful but are difficult to assess in controlled
settings [9]. Electroacupuncture provides only short-term
benefit [10], while cardiovascular conditioning has not
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been adequately studied [11–13]. Clearly an effective
treatment is lacking.
Fibromyalgia is poorly understood in neurobiological
terms with no general agreement about its aetiology and
pathogenesis. Some authorities contend it is a learned be-
havioural response to chronic stress [14], whereas others
view it in terms of a neuroendocrine abnormality [15].
These two proposed mechanisms may each lead to the
other and their manifestations may co-exist.
The symmetry of the condition leads to the hypothesis of
a central nervous system disturbance [16]. Pharmacologi-
cal interference with central pain processing can be
achieved in two ways: either by augmenting the action of
inhibitory pain pathways or by inhibiting the action of
pain pathways. Inhibitory pathway augmentation may be
achieved by noradrenergic and serotonergic drugs or by
opioids. Pain pathway inhibition may be achieved by sys-
temic administration of local anaesthetics through their
inhibition of voltage-gated sodium channels. The effec-
tiveness of the latter, particularly of IV lignocaine, in neu-
ropathic conditions is well established [17,18]. However,
the use of IV lignocaine in fibromyalgia has not been in-
vestigated extensively. The effect of a single infusion of 5
mg/kg was investigated in a small number of patients by
Sorenson [19]. This demonstrated significant pain relief
in some patients for up to five days. A previous open study
from our unit evaluated daily lignocaine infusions of 5–7
mg/kg given over 6 days to a small sample of 10 patients
[20]; this showed benefit in pain relief and mood scores at
30 day follow up, it did not address duration of pain re-
lief, other quality of life indicators or adverse effects.
The aims of the present studies were (a) to document and
quantify any adverse effects of intravenous lignocaine
therapy for fibromyalgia patients; (b) to determine if this
therapy has benefit upon pain and quality of life; and (c)
to measure the duration of benefit.
Methods
Description of therapy
The lignocaine intravenous infusional therapy was only
given to patients with evidence of normal electrocardio-
graphic conduction and normal serum electrolyte concen-
trations to minimise risks of cardiac dysrhythmias.
Patients had continuous electrocardiographic monitoring
and measurements of pulse and blood pressure every 15
minutes by automated device during infusion. They were
kept under close observation by nursing staff taught to de-
tect symptoms and signs of neurological side-effects such
as tinnitus and tunnel vision.
Serial infusions of intravenous lignocaine were given for
six consecutive days. They were started at 5 mg/kg minus
100 mg and increased by 50 mg per day to 5 mg/kg plus
150 mg, provided the maximum was no greater than 550
mg. The lignocaine was infused in Hartman's solution
500 mls over 6 hours. The infusion rate was reduced if
there was bradycardia, tachycardia, hypotension, head-
aches, dizziness, arrhythmias or tunnel vision. If slowing
the infusion failed to correct these then the infusion was
stopped.
Patients
Patients were recruited sequentially from those with fibro-
myalgia [1] scheduled for intravenous lignocaine therapy
who had not achieved sufficient symptom relief using
more "traditional" modes of treatment either in the rheu-
matology or pain relief departments. No patient was treat-
ed more than once in the study period. Adverse effects
were assessed in a prospective study of patients with fibro-
myalgia having IV lignocaine during a six-month period
this yielding just over 100 patients, a number thought
likely to provide useful information on adverse events.
The patients' nurse was requested to complete a question-
naire addressing any side-effects noted at the time of their
treatment. These adverse effects were later computed by a
third party not working on the ward. From 110 consecu-
tive patients, 106 (96%) usable questionnaires were re-
turned. The mean (range) age of this sample was 51.4
(29–74) years; 88 of the 106 (92%) were female; 72
(75%) had primary fibromyalgia, the remainder had fi-
bromyalgia secondary to osteoarthritis.
Efficacy was assessed retrospectively by sending postal
questionnaires during a different time period to another
sample of patients who had sequentially received this
therapy until 50 usable replies were obtained, this oc-
curred after sending out 55 questionnaires (91% response
rate). The smaller number was chosen because of the
greater work involved in this more lengthy questionnaire.
There was an overlap between the two samples with 29
(58%) of those investigated for efficacy being included in
the study of adverse effects. The age range of the 50 re-
sponders was 28–73 years with a mean of 50.2 ± 10.0; 40
(80%) were female; 42 (84%) had primary fibromyalgia,
the remainder had fibromyalgia secondary to osteoarthri-
tis. The mean duration of fibromyalgia was 6.6 ± 4.5 years
with a range of 1–19.
The postal questionnaire was anonymised and requested
demographic data (including duration of disease); ratings
of pain and a range of psychosocial aspects on 11-point
numerical rating scales [21,22]; and comments on use of
analgesics, General Practitioner (GP) visits and satisfac-
tion from treatment. Scoring was requested for symptoms
both prior to and following intravenous lignocaine as re-BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/21
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called by the patients. Patients who had undergone this
therapy more than once were asked to answer the ques-
tionnaire in relation to the most recent course of treat-
ment. Of the patients who responded, this applied in 37
of the 50 cases (74%); for the remainder, only one treat-
ment had been received. Demographic and clinical data
on these two groups is presented in Table 1.
Pain measuring
Pain was measured by pain score on the 11-point numer-
ical rating scale (where 0 represents no pain and 10 repre-
sents maximal imaginable pain), a four-point verbal scale
of pain severity (none, mild, moderate, severe) and aver-
age hours per day in pain. Pain relief was measured on the
11-point numerical rating scale (where 0 represents max-
imal imaginable relief and 10 represents no relief). Dura-
tion of pain improvement after treatment, and the
perceived worthiness of the treatment was also requested.
Measurement of depression, coping ability and dependen-
cy
The psychological dimension of the pain and its relief was
addressed by measurement of depression, coping ability
and dependency. These questions used the 11-point scales
with 0 to represent no depression, no dependency or no
interference with coping ability due to pain and 10 to rep-
resent maximal imaginable depression, dependency or
maximal interference with coping ability due to pain. The
sociological dimension of the pain and its relief was ad-
dressed by measurement of sleep, social life, work, house-
work, mobility, driving and sex life. These questions used
the 11-point scales with 0 to represent no interference in
the activity due to pain and 10 represented the maximum
interference imaginable in the activity due to pain.
The utilisation of healthcare resources was addressed by
measurement of patient visits to their GP before and after
treatment.
Statistical analyses
Adverse effects were analysed by frequency of occurrence.
Relationships between the aspects of the benefits of treat-
ment were analysed by Spearman's non-parametric corre-
lations. Group differences on the benefits were analysed
using chi-squared tests, Mann-Whitney U-tests and inde-
pendent samples t-tests, as appropriate; differences be-
tween pre- and post-treatment scores were analysed using
chi-squared tests, Wilcoxon signed ranks tests, and paired
samples t-tests. To account for multiple tests, Bonferroni
correction was applied and significance determined at p <
0.005.
Results
Side-effects
There were 44 documented adverse effects (42%) (Table
2), of which two were serious (2%). The commonest side-
effect was hypotension (requiring slowing or stopping in-
fusion temporarily, but none requiring other active meas-
ures). The most serious were a supraventricular
tachycardia requiring pharmacological treatment and a
case of pulmonary oedema requiring diuresis. In both of
these cases the infusion was aborted. The miscellaneous
group included infected cannula site, tissued infusion and
reaction to ECG electrode pads. None had long-term se-
quelae.
Table 1: Comparison of 1st and multiple IV lignocaine treatment groups
1st time IV lignocaine treatment multiple IV lignocaine treatments statistical analysis
Number 13 37
age (mean, SD) 54.3(4.0) 49.6(10.7) t(44) = -0.93, NS
sex (f:m) 12:1 28:9 χ 2 (1, N = 50) = 0.10, NS
Duration of FMS, yrs, mean (SD) 5.7(5.3) 6.8(4.3) t(42) = -0.11, NS
pre-treatment hrs in pain (mean, SD) 23.0(2.2) 21.8(4.5) t(42) = -0.83, NS
co-morbidity 5 9 χ 2 (1, N = 50) = 2.87, NS
Table 2: Side-effects of IV lignocaine (n = 106)
Side-Effect Number of Incidents(%)
Hypotension 17(16)
Hypertension 5 (5)
Tachycardia 1(1)
Arrythmia (SVT) 1(1)
Pulmonary Oedema 1(1)
Headache 8(8)
Nausea 1(1)
Abdominal Pain 1(1)
Increased Joint Pain 1(1)
Chest Pain 1(1)
Miscellaneous 7(7)BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/21
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Benefits
Overall, the treatment was considered to be worthwhile
by the patients, with 32 (2/3 of the valid 48 responses to
this question) responding that it was very worthwhile, 6
(1/8) responding that it was quite worthwhile, 6 respond-
ing that it was adequate and only 4 (8%) responding that
it was not worthwhile.
Pain score, pain relief interruption, mean daily duration
of pain and verbal assessment of pain all reduced signifi-
Figure 1
Pain severity pre-and post-lignocaine
Table 3: Efficacy of IV lignocaine in fibromyalgia
Dimension Variable Pre-Treatment Averagea Post-Treatment Averagea Test Statisticb P
Sensory Pain 9 5 5.74 < 0.001
Pain Relief 9 5 5.11 < 0.001
Hours/Day in Pain 22.97 17.42 4.27 < 0.001
Psychological Depression 8 5 4.32 < 0.001
Quality of life 9 6 4.94 < 0.001
Coping 9 5 5.45 < 0.001
Dependency 8 5 3.70 < 0.001
Sociological Sleep 9 5 5.20 < 0.001
Work 10 10 2.63 NS
Social Life 10 7 4.81 < 0.001
Sex Life 9 7.5 3.36 < 0.001
Driving 6.5 4.5 3.77 < 0.001
Housework 8 7 4.18 < 0.001
Mobility 9 7 4.22 < 0.001
a The reported average is the median for all variables, except in the case of Hours/Day in Pain, where the mean is given. b The reported statistic is 
the Z score converted from the Wilcoxon signed ranks test for all variables, except in the case of Hours/Day in Pain, where the t statistic is given.
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cantly (table 3 and figure 1). Verbal assessment of pain
most commonly changed from severe to moderate (figure
1), and when these ratings were converted to a 4-point nu-
merical system, the improvement was significant (Wilcox-
on W = 630, Z = 5.71, P < 0.001), and the relationship
with the 11-point pain score was moderate to strong (ρ  =
0.44 for pre-treatment scores and 0.54 for post-treatment
scores, both P < 0.001). The mean duration of pain relief
was 11.5 ± 6.5 weeks, range 0–36 weeks (Figure 2).
No differences existed between these first-time and multi-
ple-treatment patients. t(36) = 0.29, NS for post-treatment
hours of pain per day; t(43) = -1.18, NS, for the duration
of relief; and Mann-Whitney U ranged from 239.50 to
129.00, Z ranged from 1.36 to 0.05, all NS, for the non-
parametric pre- and post-treatment pain and psychosocial
variables.
Analyses of the Spearman's correlations of all pain and
psychosocial questionnaire items indicate that on average
they were only moderately related, with a mean ρ  of 0.44
(within the same time of reference), from a range of 0.00
(NS) – 0.87 (P < 0.001). However, to avoid error due to
multiple measures, Bonferroni correction was applied
with significance determined by p < 0.005.
Across all analyses of pre- and post-treatment scores, ben-
eficial change was seen in the majority of cases on most
variables: the median number of detrimental changes per
variable was 2, with a range of 0–5. Tied scores were only
moderately common, with a median number of 15 (< 1/
3) per variable, from a range of 6–28.
Psychological and sociological dimensions of pain experi-
ence were significantly improved across all domains apart
from the effect of pain upon work status (Table 3).
The median number GP visits per month reduced from
1.5 to 0.5 after treatment (Wilcoxon W = 344, Z = 3.73, P
< 0.001).
Figure 2
Duration of pain relief with IV lignocaine
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Fig 2. Duration of pain relief with IV
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Discussion
Fibromyalgia is a chronic syndrome with a variety of
symptoms including widespread muscular pain, tender-
ness, unrefreshed sleep, fatigue and is frequently associat-
ed with irritable bowel and bladder symptoms, as well as
disability, reduced quality of life and depression [4]. It is
defined in terms of pain and tenderness [1] supporting
the notion that fibromyalgia is a pain disorder.
Systemic local anaesthetics are primarily prescribed for
their antiarrhythmic actions. Short term analgesia is well
documented with intravenous lignocaine in a variety of
neuropathic pain states such as diabetes [17] and post-
herpetic neuralgia [18], and some of these patients appear
to derive prolonged relief from such treatment [23].
The mechanism of local anaesthetic infusional therapy is
conjectural. There is evidence for disordered sensory
processing both at a peripheral and at a central level in fi-
bromyalgia. Sorenson [24] showed by injecting intramus-
cular saline that there was experimentally induced
hyperexcitability in fibromyalgia patients compared with
controls. Gibson [25] described hyper-responsive somato-
sensory evoked potentials (SSEP) to laser skin stimulation
and Lorenz [26] showed there was a response to SSEP in
both hemispheres compared to controls. The reduced tha-
lamic blood flow seen on SPECT imaging [27] is similar
to that encountered in unilateral chronic neuropathic
pain using PET [28]. With evidence for disordered pain
processing centrally and peripherally in fibromyalgia one
can consider it a neuropathic condition providing a ra-
tionale for the use of systemic local anaesthetics.
Our data are similar to the other two studies of intrave-
nous lignocaine [19,20]. Both of these found significant
pain relief after treatment, and one of these which meas-
ured mood found that this also improved [20]. Other di-
mensions of pain experience were not measured in these
studies.
In the present study the magnitude of effect for pain relief
was a 4-point reduction on an 11-point scale; this is likely
to be clinically significant. It also fell outside two standard
deviations of the average after treatment compared with
before, meeting quantitative tests on statistical versus clin-
ical significance [29]. The duration of pain relief averaging
11.5 weeks is also clinically significant; however, the re-
duction in the number of hours per day in pain fell by
only 5 of the 24 hours in the day and suggests that this
therapy reduces the severity of pain rather than giving sig-
nificantly longer pain free periods.
A range of moderately related quality of life measures, that
included the psychological and sociological dimension of
pain experience, were significantly improved after treat-
ment. Notably, depression, coping, sleep, social life and
mobility all improved. The effect of pain upon work did
not change. This situation may reflect the socio-economic
factors that affect work status which are beyond therapeu-
tic control.
Most of the patients who were sent questionnaires had re-
ceived this treatment before (37 of the 50 usable replies).
It is our clinical practice to not consider repeating this
therapy if two sequential treatments are considered inef-
fective by the patient, thus one might expect a higher pro-
portion of responders to the treatment compared with an
unselected group of fibromyalgia patients. However, the
results were similar in those who had received this treat-
ment on more than one occasion and in those who had
only had the treatment once although the sample for
whom this was first treatment was small (n = 13).
The retrospective design used relies upon patient recall.
Patients can overrate past pain [30] and thus overestimate
benefits of a treatment; however, overestimates seem to
particularly occur when pain measures have increased over
the treatment period, which was not the case in this study
[31]. Pain was our primary endpoint and as a subjective
experience is difficult to measure. Rating scales are com-
monly used for their simplicity and the high associated re-
sponse rate. We chose to use a numerical rating scale as
this compares favourably against visual analogue and ver-
bal rating scales in terms of minimising scoring errors and
optimising sensitivity [21].
We included in our questionnaire a range of single ques-
tions to cover the dimensions of pain experience: the sen-
sory; affective and cognitive. Many of the multiple-item
questionnaires of these dimensions are limited by a com-
plexity that diminishes the number of patients who re-
spond. Our high response rate was achieved with simpler
numerical rating scales. Future fibromyalgia research
would profit from comparison of these single items with
more established measures of quality of life [32]. Howev-
er, similar single-item scales have been found to have ac-
ceptable properties in other pain research [21].
It is difficult to compare our results with other interven-
tional treatments since our population is highly selected
having failed these "traditional" therapies such as conven-
tional analgesics, antidepressants and physical therapies.
Nevertheless, the outcomes appear clinically significant
and all the more so for such a selected population.
We collected data on the use of health care resources since
overuse of such resources is a reason for referral. In this
area there are no established measures. We used GP visits,
which we recognise can involve any interaction, even if
the original pain problem is addressed. As such, an un-BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/21
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changed rate of visiting cannot be easily interpreted, but
the result we found, of a reduction in GP visits may be
meaningful as it indicates that less GP resources were be-
ing utilised. However, this treatment has shortcomings
from a health resources perspective. Inpatient stay with
monitoring by skilled staff and equipment is required
which is expensive. Our costs for an episode of treatment
are currently 1800 pounds sterling, which we deliver two
to three times per year. This expense is potentially justified
by the benefits of this treatment demonstrated here.
The prospective study of adverse effects of this therapy
demonstrated that side-effects occur and that all of the po-
tentially serious are cardiovascular. Other than the ar-
rhythmia and pulmonary oedema requiring
pharmacological treatment, none required an interven-
tion beyond stopping the infusion. Thus cardiovascular
monitoring of ECG and heart rate are prudent to prevent
more serious sequelae.
Comparison with other studies of our experience with
side-effects is difficult because these have not been quan-
tified before. Edwards [23] reported on 221 patients hav-
ing intravenous lignocaine therapy up to 5 mg/kg for a
variety of neuropathic pain conditions. Cardiovascular ef-
fects were mentioned as a reason to slow or stop the infu-
sion but no further details were given.
Clearly intravenous lignocaine may cause serious adverse
effects and although these appear to be uncommon this
must be considered against the fact that fibromyalgia itself
is not life-threatening. Against this risk must be set the
benefits in terms of symptom relief. In our clinical prac-
tice we inform patients of our experience with this therapy
in terms of its measured benefits and chances of risks, and
most patients elect to try it. Notably, those who have
gained symptom improvement despite adverse effects re-
quest repeated treatment with intravenous lignocaine. Pa-
tients may be best placed to balance the risks and benefits
of this therapy after being properly informed.
This study supports the benefits previously described with
intravenous lignocaine in fibromyalgia. We have been
able to quantify the magnitude and duration of effect,
which appears to be clinically significant. The side-effects
are common and potentially serious and this therapy
should be restricted to specialised hospital sites with close
surveillance.
There is a need for a larger study of an unselected patient
group and for a controlled study of this therapy to deter-
mine confidently its effects and separate the pharmaco-
logical effects of lignocaine from more indirect effects of
treatment such as inpatient hospital stay and bed rest. It is
also necessary to compare this treatment with others used
for fibromyalgia such as tricyclic antidepressants.
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